
|Podcasts|August 7, 2019
Newfound Understandings of Neuroendocrine Treatment in Kentucky
Author(s)Onclive Team
We traveled to Lexington, Kentucky, for a State of the Science Summit™ on Neuroendocrine Tumors, which featured insights from the faculty from University of Kentucky Markey Cancer Center.
Advertisement
We recently traveled to Lexington, Kentucky for a State of the Science Summit™ on Neuroendocrine Tumors. The meeting, led by experts from University of Kentucky Markey Cancer Center, spotlighted the latest management strategies in the treatment of patients with neuroendocrine tumors, starting with the diagnosis, classification, and staging of these tumors, to surgery and sequencing approaches with novel agents, such as somatostatin analogues and peptide receptor radionuclide therapy.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on OncLive
1
Long-Term Cilta-Cel Data Show Low Rates of PFS Events in Standard-Risk R/R Myeloma
2
Nonresponse to Bridging Therapy and Peak ALC After Cilta-Cel Are Associated With Neurotoxicity, NRM in Myeloma
3
FDA Updates Axi-Cel Label to Remove Limitation of Use in R/R PCNSL
4
FDA Underscores Risks Associated With DPD Deficiency and Capecitabine/5-FU Use in Cancer Care
5




































